|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
NEOPLASIA
From the Division of Hematology/Oncology, Department of
Pathology, Brigham and Women's Hospital, and the Howard Hughes Medical
Institute, Harvard Medical School, Boston, MA; and Department of
Pathology, Emory University, Atlanta, GA.
FLT3 receptor tyrosine kinase is expressed on lymphoid and myeloid
progenitors in the hematopoietic system. Activating mutations in FLT3
have been identified in approximately 30% of patients with acute
myelogenous leukemia, making it one of the most common mutations
observed in this disease. Frequently, the mutation is an in-frame
internal tandem duplication (ITD) in the juxtamembrane region that
results in constitutive activation of FLT3, and confers interleukin-3
(IL-3)-independent growth to Ba/F3 and 32D cells. FLT3-ITD mutants
were cloned from primary human leukemia samples and assayed for
transformation of primary hematopoietic cells using a murine bone
marrow transplantation assay. FLT3-ITDs induced an oligoclonal
myeloproliferative disorder in mice, characterized by splenomegaly and
leukocytosis. The myeloproliferative phenotype, which was associated
with extramedullary hematopoiesis in the spleen and liver, was
confirmed by histopathologic and flow cytometric analysis. The disease
latency of 40 to 60 days with FLT3-ITDs contrasted with wild-type FLT3
and enhanced green fluorescent protein (EGFP) controls, which did not
develop hematologic disease (> 200 days). These results demonstrate
that FLT3-ITD mutant proteins are sufficient to induce a
myeloproliferative disorder, but are insufficient to recapitulate the
AML phenotype observed in humans. Additional mutations that impair
hematopoietic differentiation may be required for the development of
FLT3-ITD-associated acute myeloid leukemias. This model system should
be useful to assess the contribution of additional cooperating
mutations and to evaluate specific FLT3 inhibitors in vivo.
(Blood. 2002;99:310-318) FLT3 (FMS-like receptor tyrosine kinase) also
referred to as fetal liver kinase 2 (FLK-2) or stem cell tyrosine
kinase 1 (STK-1) was originally described as a tyrosine kinase receptor
with strong sequence similarity to FMS, KIT, and platelet-derived
growth factor receptor (PDGFR).1,2 These proteins are all
members of the receptor tyrosine kinase type (RTK) III subfamily based
on a common domain structure including an interrupted kinase domain
(for review, see Rosnet and Birnbaum3). FLT3 is expressed
by cells found in the hematopoietic stem cell compartment
(Sca1+, Lin It is therefore interesting that activating mutations in FLT3 have been
found in approximately 25% to 30% of patients with acute myelogenous
leukemia (AML).9,10 The majority of FLT3 mutations are
internal tandem duplications (ITDs) in the juxtamembrane domain encoded
by exon 11, and were first reported in patients with AML in
1996.11 This mutation appears to confer a poor prognosis in several studies reported to date.12-14 All ITD repeats
were in-frame, but varied significantly in length. No such ITD
abnormalities were detected in remission samples, indicating that these
were acquired mutations.11 Subsequent studies have
confirmed the presence of the juxtamembrane ITDs in human leukemias,
with an overall incidence of approximately 20% in AML. In addition,
substitution mutations in the FLT3 kinase domain at Asp835 have
recently been reported in approximately 7% of patients with
AML.10 Both the FLT3-ITD and FLT3-Asp835 mutations
result in constitutive activation of the receptor and are associated
with FLT3 autophosphorylation and phosphorylation of downstream targets
such as STAT5 and mitogen-activated protein (MAP)
kinase.15-18 FLT3-ITD mutations are also found but at much
lower frequencies in related diseases such as myelodysplastic syndrome
(< 5%)9,10,19 and have rarely been identified in acute
lymphocytic leukemia (ALL) unless they are biphenotypic.20
Constitutive activation of RTKs is not unprecedented in leukemias;
however, the vast proportion of activated RTKs studied thus far are
associated with chronic myelogenous leukemia (CML) phenotypes and occur
as a result of a chromosomal translocation. Examples include the
BCR/ABL, TEL/PDGF Activating mutations in FLT3 differ from tyrosine kinase fusions
associated with the CML phenotypes. FLT3-ITD and activating loop
mutants are localized to the plasma membrane as opposed to the
cytoplasmic localization of tyrosine kinase fusions. The residual tyrosine kinase allele in the tyrosine kinase fusions
associated with chromosomal translocations is typically either
expressed at low levels or is localized to a different subcellular
compartment than the tyrosine kinase fusion. In contrast, both the
wild-type and FLT3-ITD alleles are expressed at comparable levels and
are localized to the plasma membrane where they may interact. Perhaps most importantly, activating mutations in FLT3 are most frequently associated with AML rather than CML phenotypes.9
Furthermore, FLT3-ITDs are most often observed in AML patients negative
for other cytogenetic abnormalities.14 Taken together,
these data suggest that FLT3-ITDs may play a critical role in the
development of AML.
We have investigated the transforming properties of the FLT3-ITD in
primary hematopoietic cells using a murine BMT assay. We report that
the FLT3-ITDs cloned from primary human myeloid leukemias confer
factor-independent growth to Ba/F3 cells and induce a
myeloproliferative phenotype similar to that observed with the
translocation-associated tyrosine kinase fusions. These data have
important implications for the contribution of the FLT3-ITD to the
pathogenesis of human AML. Furthermore, this model should provide a
useful system for analysis of cooperativity of FLT3 with other
mutations and gene rearrangements associated with human leukemia and
for testing of FLT3-specific low molecular weight inhibitors.
Cloning and vector construction
All FLT3 mutations were confirmed by sequencing and the entire cDNA was
subcloned from pGEM to MSCV-EB neo42 or MSCV2.2 GFP
(kindly provided by W. Pear, University of Pennsylvania)43 into the HpaI site in each case.
Cell culture and virus production
Mouse strains and BMT BALB/c mice were purchased from Taconic (Germantown, NY). BMT assays were carried out as described previously.32,44 Briefly, 4- to 6-week-old male donor mice were primed with intraperitoneal injection of 5'-fluorouracil (150 mg/kg, Sigma, St Louis, MO) and subsequently killed after 6 days by CO2 asphyxiation. Bone marrow was flushed from femurs and tibias, and red blood cells were lysed (Red Blood Cell Lysis, RBCL buffer, Sigma). Cells were cultured overnight with IL-3 (6 ng/mL, R & D Systems), IL-6 (10 ng/mL, R & D systems), and stem cell factor (10 ng/mL, Peprotech, Rocky Hill, NJ) in RPMI with 10% FCS (transplant medium). Cells were transduced by 2 rounds of spin-infection, at 24 hours and 48 hours after harvesting. Centrifugation of 1 mL viral supernatant and 4 × 106 cells in 3 mL transplant media containing 5 µg/mL Polybrene and 7.5 mM HEPES buffer was carried out for 90 minutes at 1800g. Cells were washed in PBS, resuspended in Hanks balanced salt solution (Life Technologies) and injected (5 × 105 cells/0.5 mL) into the lateral tail vein of lethally irradiated (2 × 450 cGy) female recipient mice. Mice were housed in microisolator cages with autoclaved chow and acidified water.Histopathology Murine tissues were fixed for at least 72 hours in 10% neutral buffered formalin (Sigma), dehydrated in alcohol, cleared in xylene, and infiltrated with paraffin on an automated processor (Leica, Bannockburn, IL). The tissue sections (4 µm thick) from paraffin-embedded tissue blocks were placed on charged slides and deparaffinized in xylene, rehydrated through graded alcohol solutions, and stained with hematoxylin and eosin. To visualize the reticulin fibers, rehydrated sections were sequentially treated with potassium permanganate (0.5%), potassium metabisulfite (2%), ferric ammonium sulfate (2%), ammonical silver solution, formalin (10%), gold chloride (0.2%), potassium metasulfite (2%), sodium thiosulfate (2%), and counterstained with methyl green dye according to the published method.45Flow cytometric immunophenotyping and fluorescence-activated cell sorting Single-cell suspensions of spleen, bone marrow, and blood were prepared as described previously.32,44 Briefly, red blood cells were lysed in RBCL buffer (Sigma) for 5 minutes at room temperature and frozen in 90% fetal bovine serum and 10% dimethyl sulfoxide. Prior to analysis, cells were washed in PBS/0.1% NaN3/0.1% bovine serum albumin (BSA) and preincubated for 20 minutes on ice with supernatant from the 2.4G2 hybridoma cell line (anti-CD16/CD32; American Type Culture Collection, Rockville, MD) to block nonspecific Fc receptor-mediated binding. Cells were stained for 20 minutes on ice with monoclonal antibodies, washed in staining buffer, and stained with secondary antibodies where necessary. Antibodies used were allophycocyanin (APC)-conjugated Gr-1 and CD4; phycoerythrin (PE)-conjugated Mac 1, Thy 1.2, and CD8; biotin-conjugated CD19; and APC-conjugated streptavidin. All antibodies were purchased from Pharmingen, San Diego, CA apart from APC-CD4 and APC streptavidin, which were purchased from Caltag, Burlingame, CA. Flow cytometric analysis was carried out using a 4-color FACSort cytometer (Becton Dickinson, Mountain View, CA) and analyzed using CellQuest software.Fluorescence-activated cell sorting (FACS) was performed on a Coulter
Epics Altra at approximately 15 000 cells/s. A single cell suspension
from the spleen was resuspended in 1% BSA in PBS at 107
cells/mL and sorted into EGFP+ and EGFP Southern analysis DNA was prepared using a PUREGENE DNA isolation kit according to the manufacturer's protocol (Gentra Systems, Minneapolis, MN). After enzymatic digestion of 20 µg DNA with either EcoRI or XhoI and electrophoretic separation, the genomic DNA was blotted to Hybond-N+ nylon membranes (Amersham, Arlington Heights, IL) by capillary transfer.46 The green fluorescent protein (GFP) probe was a 750-bp fragment isolated using a NcoI/SalI digest from MSCV-EGFP. The 500-bp granzyme A probe was a kind gift from J. Pollock and T. Ley, Washington University. Probes were labeled with 32P by random priming using Radprime (Life Technologies), and Southern hybridization was performed as described.32Western analysis The Ba/F3 cells were washed 3 times in PBS and lysed in 10 mM Tris pH 7.5, 130 mM NaCl, 1% Triton X-100, 10 mM NaF, 10 mM sodium phosphate, 10 mM sodium pyrophosphate, 10 mM EDTA, 1 mM sodium vanadate, and protease inhibitor cocktail tablets (Roche-Boehringer, Indianapolis, IN). Total cell lysate (150 µg) was separated on a 7.5% gel and Western analysis was performed as described previously44 using a 1:200 dilution of anti-FLT3 SC-479 (Santa Cruz, Santa Cruz, CA) as the primary antibody, followed by horseradish peroxidase-conjugated secondary antibody (Amersham Life Science) and visualization by enhanced chemoluminescence (Amersham Life Science).
Cloning of FLT3-ITD mutations from primary human AML cells The DNA samples from peripheral blood of 12 patients with AML were screened by PCR (see "Materials and methods") for length mutations in the juxtamembrane region, encoded by exon 11. Four independent FLT3-ITD mutants were cloned, which had a duplicated sequence of between 7 and 25 amino acids (Figure 1). The length and position of the duplication varied between samples and differed from other published FLT3-ITD mutants.9,11,13,15 No abnormalities were observed in samples from 54 healthy individuals, consistent with published data.9 Each FLT3-ITD mutant, including a previously reported FLT3-ITD mutant (Npos is Mut117) positive control, and the wild-type FLT3 gene were subcloned into a MSCV murine ecotropic retrovirus that expressed either the neomycin selectable marker or the EGFP under the control of an internal ribosome entry site (IRES).
Expression and transforming properties of FLT3 and FLT3 mutants in Ba/F3 cells To confirm that the FLT3-ITD mutants we cloned had similar properties to those previously reported, Ba/F3 cells were stably transduced with MSCV-neo retrovirus containing either the wild-type FLT3 or FLT-ITD cDNAs. Pools of transduced cells were maintained in IL-3 and selected with G418 for 2 weeks prior to analysis of factor-independent growth. Each of the FLT3-ITD mutants including the previously reported positive control Npos,17 conferred IL-3 factor-independent growth to Ba/F3 cells. Parental cells or cells stably transduced with the wild-type FLT3 died after IL-3 deprivation (Figure 2A). There were no significant differences in growth rates in replicate experiments over the time course of this assay. A point mutation in the activation loop that inhibits kinase activity of wild-type FLT347 abrogated transforming activity of FLT3-ITD when mutated in the context of W51 (data not shown). Western blot analysis confirmed that the cell pools expressed comparable levels of FLT3 and each FLT3-ITD mutant at the expected molecular weights of approximately 130 and 155 kd (Figure 2B), and that parental Ba/F3 cells did not express FLT3 (Figure 2B). The FLT3 wild-type protein was identified by immunoprecipitation analysis as 2 distinct bands of approximately 130 and 155 kd, respectively. It has been previously demonstrated by expression in COS-1 and COS-7 cells that these 2 bands are generated from a predicted 110-kd protein via posttranslational glycosylation.15,47
Two independent FLT3-ITD mutants, but not wild-type FLT3, induce a lethal myeloproliferative disease in a murine BMT assay Donor mice were treated with 5-fluorouracil to increase the number of cycling stem cells for retroviral transduction, as described in "Materials and methods." Equivalent titers of FLT3-ITD or FLT3 were then transduced into primary mouse bone marrow cells using the MSCV-EGFP retrovirus. Transduced bone marrow for each construct was also analyzed by flow cytometry to confirm EGFP expression in a comparable fraction of the transplanted cells. Transduced bone marrow cells were transferred by injection into the lateral tail vein of lethally irradiated syngeneic recipient mice. Mice receiving transplants of cells transduced with retrovirus containing the wild-type FLT3 or the MSCV vector expressing EGFP engrafted normally and had a normal survival with a follow-up of more than 200 days (Figure 3). In contrast, animals transduced with cells containing either the FLT3-ITD/51 or FLT3-ITD/78 developed a lethal hematopoietic disease with a median latency of approximately 40 to 50 days (Figure 3 and Table 1).
Animals receiving transplants of FLT3-ITD developed marked
leukocytosis, with a white blood cell (WBC) count ranging from 28 to
145 × 103/µL (Table 1). Differential counts analyzed
by the scatter property of peripheral blood of several animals
indicated that the increase in WBCs was due almost entirely to
neutrophils, which were increased from between 13.7% to 21.8% in 3 controls to 75.7% to 87% in 3 FLT3-ITD-diseased animals analyzed.
Animals with FLT3-ITD-induced disease appeared to have a higher
proportion of mature neutrophils with fewer immature myeloid cells
observed than in animals with myeloproliferative disease associated
with other tyrosine kinase fusions.28 The absolute numbers
of other blood cells were unchanged and no abnormality in erythrocyte
count or composition was observed. Wright-Giemsa stains of peripheral
blood demonstrated leukocytosis with myeloid lineage cells in all
stages of maturation, predominantly terminally differentiated
neutrophils (Figure 4A).
Gross pathologic examination demonstrated emaciation, ruffled fur, and
marked splenomegaly, with spleen weights ranging from 300 to 1000 mg in
FLT3-ITD/51 and 250 to 900 mg in FLT3-ITD/78 compared to 100 to 171 mg
in wild-type FLT3 or EGFP controls (Table 1). The slight increase in
spleen weight in the controls was typical for animals after irradiation
and BM transplantation. Bone marrow stained with hematoxylin-eosin
demonstrated hypercellularity with a marked predominance of maturing
myeloid lineage cells, consistent with a myeloproliferative disease
(Figure 4B). In addition, the bone marrow, as in other mouse models of
myeloproliferative disease,48 displayed a significant
degree of reticulin fibrosis as demonstrated by silver stain when
compared to control FLT3 mice (Figure 4E,F). A reduced yield of cells
was obtained from the marrow of FLT3-ITD animals compared to EGFP and
wild-type FLT3 controls. Splenic architecture was effaced by a marked
expansion of red pulp comprised of maturing myeloid cells (Figure 4C)
and scattered admixed megakaryocytes (not shown). Analysis of the liver
demonstrated a perivascular parenchymal infiltration comprised predominantly of maturing myeloid elements, with admixed erythroid and
megakaryocytic elements similar to that seen in the spleen (Figure 4D).
The lungs showed evidence of pulmonary hemorrhage, as observed in BMT
assays with other tyrosine kinase fusions such as with
TEL/PDGF Flow cytometric analysis of blood and spleen cells from FLT3-ITD mice
further confirmed the myeloproliferative phenotype. Several FLT3-ITD
animals were examined in detail showing 57% to 70% of cells in the
spleen (n = 3) and 70% to 90% of cells in the blood (n = 5) were
positive for the late myeloid markers Gr-1 (Ly 6-G) and Mac-1,
indicative of mature neutrophils, compared to 5% to 9% and 16% to
24% Gr-1, Mac-1 double-positive cells in spleen and blood of controls,
respectively. A representative set of samples of one EGFP control, one
wild-type FLT3, and one FLT3-ITD are presented in Figure
5. Gr-1+ cells were also
EGFP+, consistent with proviral integration in these cells.
In addition, significant proportions of Gr-1+ cells were
EGFP
No abnormalities were observed in T-cell (Figure 5A) or B-cell (Figure 5A, B) populations. Comparable results were obtained from immunophenotypic analysis of cells from the bone marrow (n = 4), with an increase in Gr-1+ cells from 54% on average in controls to 87% average in FLT3-ITD mice. Southern blot analysis of spleen, bone marrow, and blood
demonstrated proviral integration in all affected tissues. Data from the spleen are shown in Figure 6, where
the DNA was digested to excise the proviral DNA as a single band (3 kb
for MSCV-EGFP or 6 kb for the FLT3 series in MSCV-EGFP) or cleaved once
within the construct and randomly in the flanking DNA, according to the insertion position, which demonstrated the clonality. DNA integrity and
equal loading was demonstrated by reprobing the blot for an endogenous
gene, granzyme A (Figure 6, lower panel). Southern blot analysis of
control mice sacrificed at the same time confirmed transduction of bone
marrow cells with FLT3-ITD and MSCV-EGFP, although these animals did
not develop disease. Restriction digests designed to determine
clonality indicated that the myeloproliferative disease induced by the
FLT3-ITD was oligoclonal (Figure 6, upper panel).
This is the first demonstration that expression of FLT3-ITD, but not wild-type FLT3, has transforming properties in primary bone marrow cells. FLT3-ITD expression causes a myeloproliferative phenotype characterized by leukocytosis and comprised mainly of mature neutrophils. Splenomegaly with extramedullary hematopoiesis in the spleen and the liver are also consistently observed. Myeloproliferative disease induced by FLT3-ITD has a latency of 40 to 60 days and is oligoclonal. These findings demonstrate that FLT3-ITD is sufficient to induce a
myeloproliferative disease. However, although the FLT3-ITD is primarily
associated with AML in humans, it is not sufficient to induce an AML
phenotype in the murine BMT assay. These data suggest that FLT3-ITDs
may require additional cooperating mutations to generate the AML
phenotype. Evidence supporting this hypothesis includes clinical
observations that FLT3-ITD may coexist with virtually any known
chromosomal translocation associated with AML, including the t(8;21),
inv(16), and t(15;17) associated with the AML1/ETO,
CBF Initial analysis suggests that FLT3 and FLT3-ITD use the same signal
transduction pathways. On stimulation with FL, FLT3 activates signal
transduction pathways through engagement of SH2-containing proteins,
including PLC The mechanism by which the ITD activates the FLT3 tyrosine kinase is not understood. However, insertion of the duplicated residues may disrupt a kinase inhibitory domain, resulting in kinase activation. Several lines of evidence support this hypothesis. First, FLT3-ITD in-frame mutations in patients with AML may range in size from several to more than 40 amino acids and vary in position within the juxtamembrane domain. In addition, it has recently been demonstrated that deletion of several amino acid residues in the juxtamembrane domain of FLT3 also results in constitutive activation of FLT3.58 The observation that a spectrum of insertions or deletions in the JM domain serve to activate the kinase is most consistent with loss of function of a kinase inhibitory domain through disruption of the tertiary structure. Second, in-frame deletions in the juxtamembrane domain of c-KIT, a related type III receptor tyrosine kinase, results in constitutive activation of c-KIT in gastrointestinal stromal cell tumors and mastocytoses.63,64 Third, regulation of the FLT1 receptor tyrosine kinase through an autoinhibitory function of the JM domain has recently been reported.65 Collectively, these data support the hypothesis that disruption of an autoinhibitory motif in the JM domain, either by deletion or insertion, results constitutive activation of the FLT3 kinase. Structural analysis of FLT3 and related mutants will be required to confirm this hypothesis. An additional question regarding the mechanism of FLT3-ITD transformation relates to the involvement of the wild-type FLT3 in modulating the signal transduction by the mutant. It is plausible that wild-type FLT3 could potentiate or impair signal transduction by FLT3-ITD. The data from the FLT3-ITD murine BMT assay are consistent with previously reported data on the role of FL and FLT3 receptor in hematopoiesis. FL synergizes with other growth factors in colony assays to stimulate proliferation of hematopoietic progenitors and myeloid precursors but not erythroid precursors.66,67 Furthermore, mice that do not express the FLT3 receptor have reduced B lymphopoiesis.68 On transplantation, reduced T lymphopoiesis and myelopoiesis are also observed.68 Mice that lack FL have reduced numbers of myeloid and B-lymphoid progenitors and a deficiency in natural killer and dendritic cells.69 In addition, mice treated with exogenous FL accumulate progenitor cells in the peripheral blood.70 Overexpression of FL in a BMT assay induces a proliferative phenotype71 and can predispose animals to leukemia after a 5-month latency period where the malignant cells were all shown to express FLT3.72 Taken together these data suggest that the FLT3-FL signaling pathway has a unique role in expansion of stem and progenitor cells and sustained activation of FLT3 can lead to hyperproliferation of cells expressing the FLT3 receptor. Our findings confirm the role of FLT3 in cellular proliferation and support the hypothesis that FLT3-ITD mutations contribute to the pathogenesis of human leukemias. Each independent FLT3-ITD mutant tested was sufficient to induce a myeloproliferative disease in the murine BMT assay, a phenotype similar to that generated by the activated tyrosine kinases that result from chromosomal translocations.21-38,40,41 These data suggest that it may be worthwhile to investigate other myeloproliferative syndromes, such as myeloid metaplasia with myelofibrosis, polycythemia vera, and essential thrombocythemia, for the presence of activating mutations in FLT3. Finally, the recently reported successes in the therapy of chronic myelogenous leukemias associated with the BCR/ABL gene rearrangement with the ABL-specific kinase inhibitor STI57173,74 suggest that small molecule inhibitors of FLT3 may have therapeutic efficacy in AML.75 This murine model should also allow pharmacologic and therapeutic properties of small molecule inhibitors to be tested in vivo.
We thank L. Seaton for administrative assistance. We thank J. Daley and S. Lazo for expert cell sorting, and D. Cain and S. Amaral for technical support. We also thank E. Anastasiadou, A. Dash, D. Sternberg, and other members of the Gilliland and Tenen laboratories for valuable discussions.
Submitted May 7, 2001; accepted September 4, 2001.
Supported in part by National Institutes of Health grants CA66996 and DK50654. L.M.K. is an associate and D.G.G. is an associate investigator of the Howard Hughes Medical Institute.
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: D. Gary Gilliland, Harvard Institutes of Medicine, 4 Blackfan Cir, Rm 418, Boston, MA 02115; e-mail: gilliland{at}calvin.bwh.harvard.edu.
1.
Matthews W, Jordan C, Gavin M, Jenkins N, Copeland N, Lemischka I.
A receptor tyrosine kinase cDNA isolated from a population of enriched primitive hematopoietic cells and exhibiting close genetic linkage to c-kit.
Proc Natl Acad Sci U S A.
1991;88:9026-9039 2. Rosnet O, Marchetto S, deLapeyriere O, Birnbaum D. Murine Flt3, a gene encoding a novel tyrosine kinase receptor of the PDGFR/CSF1R family. Oncogene. 1991:641-650. 3. Rosnet O, Birnbaum D. Hematopoietic receptors of class III receptor-type tyrosine kinases. Crit Rev Oncog. 1993;4:595-613[Medline] [Order article via Infotrieve].
4.
Zeigler FC, Bennett BD, Jordan CT, et al.
Cellular and molecular characterization of the role of the flk-2/flt-3 receptor tyrosine kinase in hematopoietic stem cells.
Blood.
1994;84:2422-2430
5.
Rappold I, Ziegler BL, Kohler I, et al.
Functional and phenotypic characterization of cord blood and bone marrow subsets expressing FLT3 (CD135) receptor tyrosine kinase.
Blood.
1997;90:111-125 6. Shurin M, Esche C, Lotze M. FLT3: receptor and ligand. Biology and potential clinical application. Cytokine Growth Factor Rev. 1998;9:37-48[CrossRef][Medline] [Order article via Infotrieve].
7.
Muench MO, Roncarolo MG, Menon S, et al.
FLK-2/FLT-3 ligand regulates the growth of early myeloid progenitors isolated from human fetal liver.
Blood.
1995;85:963-972
8.
Molineux G, McCrea C, Yan XQ, Kerzic P, McNiece I.
Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential.
Blood.
1997;89:3998-4004 9. Yokota S, Kiyoi H, Nakao M, et al. Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines. Leukemia. 1997;11:1605-1609[CrossRef][Medline] [Order article via Infotrieve].
10.
Yamamoto Y, Kiyoi H, Nakano Y, et al.
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.
Blood.
2001;97:2434-2439 11. Nakao M, Yokota S, Iwai T, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911-1918[Medline] [Order article via Infotrieve].
12.
Kiyoi H, Naoe T, Nakano Y, et al.
Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.
Blood.
1999;93:3074-3080 13. Abu-Duhier FM, Goodeve AC, Wilson GA, et al. FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group. Br J Haematol. 2000;111:190-195[CrossRef][Medline] [Order article via Infotrieve].
14.
Meshinchi S, Woods WG, Stirewalt DL, et al.
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia.
Blood.
2001;97:89-94 15. Kiyoi H, Towatari M, Yokota S, et al. Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia. 1998;12:1333-1337[CrossRef][Medline] [Order article via Infotrieve]. 16. Fenski R, Flesch K, Serve S, Mizuki M, et al. Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br J Haematol. 2000;108:322-330[CrossRef][Medline] [Order article via Infotrieve]. 17. Hayakawa F, Towatari M, Kiyoi H, et al. Tandem-duplicated Flt3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene. 2000;19:624-631[CrossRef][Medline] [Order article via Infotrieve]. 18. Tse K-F, Mukherjee G, Small D. Constitutive activation of FLT3 stimulates multiple intracellular signal transducers and results in transformation. Leukemia. 2000;14:1766-1776[CrossRef][Medline] [Order article via Infotrieve]. 19. Horiike S, Yokota S, Nakao M, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia. 1997;11:1442-1446[CrossRef][Medline] [Order article via Infotrieve]. 20. Xu F, Taki T, Yang H, et al. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br J Haematol. 1999;105:155-162[CrossRef][Medline] [Order article via Infotrieve].
21.
Daley GQ, McLaughlin J, Witte ON, Baltimore D.
The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts.
Science.
1987;237:532-535 22. Matulonis U, Salgia R, Okuda K, Druker B, Griffin JD. Interleukin-3 and p210 BCR/ABL activate both unique and overlapping pathways of signal transduction in a factor-dependent myeloid cell line. Exp Hematol. 1993;21:1460-1466[Medline] [Order article via Infotrieve].
23.
Pendergast AM, Gishizky ML, Havlik MH, Witte O.
SH1 domain autophosphorylation of P210 BCR/ABL is required for transformation but not growth factor independence.
Mol Cell Biol.
1993;13:1728-1736 24. Pendergast AM, Quilliam LA, Cripe LD, et al. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adapter protein. Cell. 1993;75:175-185[CrossRef][Medline] [Order article via Infotrieve].
25.
Ilaria RLJ, Van Etten RA.
P210 and P190(BCR/ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members.
J Biol Chem.
1996;271:31704-31710
26.
Carroll M, Tomasson MH, Barker GF, Golub TR, Gilliland DG.
The TEL/platelet-derived growth factor
27.
Carroll M, Ohno-Jones S, Tamura S, et al.
CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins.
Blood.
1997;90:4947-4952
28.
Tomasson MH, Williams IR, Hasserjian R, et al.
TEL/PDGF
29.
Tomasson MH, Sternberg DW, Williams IR, et al.
Fatal myeloproliferation, induced in mice by TEL/PDGF 30. Wilbanks AM, Mahajan S, Frank DA, Druker BJ, Gilliland DG, Carroll M. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins. Exp Hematol. 2000;28:5.
31.
Lacronique V, Boureux A, Valle VD, et al.
A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Science.
1997;278:1309-1312 32. Schwaller J, Frantsve J, Tomasson M, et al. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myeloid and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion gene. EMBO J. 1998;17:5321-5333[CrossRef][Medline] [Order article via Infotrieve]. 33. Schwaller J, Parganas E, Wang D, et al. Stat5a/b is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000;6:693-704[CrossRef][Medline] [Order article via Infotrieve].
34.
Ross TS, Bernard OA, Berger R, Gilliland DG.
Fusion of Huntingtin interacting protein 1 to PDGF
35.
Ross TS, Gilliland DG.
Transforming properties of the Huntingtin interacting protein 1/platelet-derived growth factor beta receptor fusion protein.
J Biol Chem.
1999;274:22328-22336
36.
Kulkami S, Heath C, Partker SEA.
Fusion of H4/D10S170 to the platelet-derived growth factor receptor beta in BCR/ABL negative myeloproliferative disorders with a t(5;10)(q33;q21).
Cancer Res.
2000;60:3592-3598
37. Schwaller J, Anastasiadou A, Cain D, et al. H4(D10S170), a gene
frequently rearranged in papillary thyroid carcinoma, is fused to the
platelet-derived growth factor receptor 38. Golub TR, Goga A, Barker G, et al. Oligomerization of the ABL tyrosine kinase by the ETS protein TEL in human leukemia. Mol Cell Biol. 1996;16:4107-4116[Abstract]. 39. Sawyers CL. Molecular abnormalities in myeloid leukemias and myelodysplastic syndromes. Leuk Res. 1998;22:1113-1122[CrossRef][Medline] [Order article via Infotrieve].
40.
Papadopoulos P, Ridge SA, Boucher CA, Stocking C, Wiedemann LM.
The novel activation of ABL by fusion to an ets-related gene, TEL.
Cancer Res.
1995;55:34-38
41.
Peeters P, Raynaud SD, Cools J, et al.
Fusion of TEL, the ETS-variant gene 6 (ETV6), to the receptor-associated kinase JAK2 as a result of t(9;12) in a lymphoid and t(9;15;12) in a myeloid leukemia.
Blood.
1997;90:2535-2540 42. Hawley RG, Lieu FH, Fong AZ, Hawley TS. Versatile retroviral vectors for potential use in gene therapy. Gene Ther. 1994;1:136-138[Medline] [Order article via Infotrieve].
43.
Persons DA, Allay JA, Allay ER, et al.
Retroviral-mediated transfer of the green fluorescent protein gene into murine hematopoietic cells facilitates scoring and selection of transduced progenitors in vitro and identification of genetically modified cells in vivo.
Blood.
1997;90:1777-1786 44. Liu Q, Schwaller J, Kutok J, et al. Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 2000;19:1827-1838[CrossRef][Medline] [Order article via Infotrieve]. 45. Gomori G. Silver impregnation of reticulum in paraffin sections. Am J Pathol. 1937;13:993-1002. 46. Sambrook J, Maniatis T. Molecular Cloning: A Laboratory Manual. 2nd ed. New York: CSHL Press; 1989. 47. Maroc N, Rottapel R, Rosnet O, et al. Biochemical characterization and analysis of the transforming potential of the FLT3/FLK2 receptor tyrosine kinase. Oncogene. 1993;8:909-918[Medline] [Order article via Infotrieve]. 48. Schwaller J, Parganas E, Wang D, et al. Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2. Mol Cell. 2000;6:693-704.
49.
Zhang X, Ren R.
Bcr-Abl efficiently induces a myeloproliferative disease and production of excess interleukin-3 and granulocyte-macrophage colony-stimulating factor in mice: a novel model for chronic myelogenous leukemia.
Blood.
1998;92:3829-3840
50.
Tomasson MH, Williams IR, Li S, et al.
Induction of myeloproliferative disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
Blood.
2001;97:1435-1441
51.
Grisolano JL, Wesselschmidt RL, Pelicci PG, Ley TJ.
Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR alpha under control of cathepsin G regulatory sequences.
Blood.
1997;89:376-387
52.
He LZ, Tribioli C, Rivi R, et al.
Acute leukemia with promyelocytic features in PML/RARalpha transgenic mice.
Proc Natl Acad Sci U S A.
1997;94:5302-5307
53.
Okuda T, Cai Z, Yang S, et al.
Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.
Blood.
1998;91:3134-3143 54. Castilla LH, Garrett L, Adya N, et al. The fusion gene Cbfb-MYH11 blocks myeloid differentiation and predisposes mice to acute myelomonocytic leukaemia. Nat Genet. 1999;23:144-146[CrossRef][Medline] [Order article via Infotrieve].
55.
Rhoades KL, Hetherington CJ, Harakawa N, et al.
Analysis of the role of AML1-ETO in leukemogenesis, using an inducible transgenic mouse model.
Blood.
2000;96:2108-2115
56.
Dosil M, Wang S, Lemischka IR.
Mitogenic signaling and substrate specificity of the Flk2/Flt3 receptor tyrosine kinase in fibroblasts and interleukin 3-dependent hematopoietic cells.
Mol Cell Biol.
1993;13:6572-6585 57. Rottapel R, Turck C, Casteran N, et al. Substrate specificities and identification of a putative binding site for PI3K in the carboxy tail of the murine Flt3 receptor tyrosine kinase. Oncogene. 1994;9:1755-1765[Medline] [Order article via Infotrieve].
58.
Mizuki M, Fenski R, Halfter H, et al.
Flt3 mutations from patients with acute myeloid leukemia induce transformation of 32D cells mediated by the Ras and STAT5 pathways.
Blood.
2000;96:3907-3914
59.
Birg F, Courcoul M, Rosnet O, et al.
Expression of the FMS/KIT-like gene FLT3 in human acute leukemias of the myeloid and lymphoid lineages.
Blood.
1992;80:2584-2593 60. Meierhoff G, Dehmel U, Gruss HJ, et al. Expression of FLT3 receptor and FLT3-ligand in human leukemia-lymphoma cell lines. Leukemia. 1995;9:1368-1372[Medline] [Order article via Infotrieve]. 61. Zhang S, Mantel C, Broxmeyer H. Flt3 signaling involves tyrosyl-phosphorylation of SHP-2 and SHIP and their association with Grb2 and Shc in Baf3/Flt3 cells. J Leukoc Biol. 1999;65:372-380[Abstract].
62.
Zhang S, Fukuda S, Lee Y, et al.
Essential role of signal transducer and activator of transcription (Stat)5a but not Stat5b for Flt3-dependent signaling.
J Exp Med.
2000;192:719-728 63. Boissan M, Feger F, Guillosson JJ, Arock M. c-Kit and c-kit mutations in mastocytosis and other hematological diseases. J Leukoc Biol. 2000;67:135-148[Abstract].
64.
Hirota S, Isozaki K, Moriyama Y, et al.
Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
Science.
1998;279:577-580 65. Gille H, Kowalski J, Yu L, et al. A repressor sequence in the juxtamembrane domain of Flt-1 (VEGFR-1) constitutively inhibits vascular endothelial growth factor-dependent phosphatidylinositol 3'-kinase activation and endothelial cell migration. EMBO J. 2000;19:4064-4073[CrossRef][Medline] [Order article via Infotrieve].
66.
Jacobsen SE, Okkenhaug C, Myklebust J, Veiby OP, Lyman SD.
The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro: synergistic interactions with interleukin (IL) 11, IL-12, and other hematopoietic growth factors.
J Exp Med.
1995;181:1357-1363
67.
Piacibello W, Fubini L, Sanavio F, et al.
Effects of human FLT3 ligand on myeloid leukemia cell growth: heterogeneity in response and synergy with other hematopoietic growth factors.
Blood.
1995;86:4105-4114 68. Mackarehtschian K, Hardin JD, Moore KA, Boast S, Goff SP, Lemischka IR. Targeted disruption of the flk2/flt3 gene leads to deficiencies in primitive hematopoietic progenitors. Immunity. 1995;3:147-161[CrossRef][Medline] [Order article via Infotrieve].
69.
McKenna H, Stocking K, Miller R, et al.
Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells.
Blood.
2000;95:3489-3497
70.
Brasel K, McKenna H, Morrissey P, et al.
Hematologic effects of flt3 ligand in vivo in mice.
Blood.
1996;88:2004-2012
71.
Juan T, McNiece I, Van G, et al.
Chronic expression of murine flt3 ligand in mice results in increased circulating white blood cell levels and abnormal cellular infiltrates associated with splenic fibrosis.
Blood.
1997;90:76-84
72.
Hawley TS, Fong AZ, Griesser H, Lyman SD, Hawley RG.
Leukemic predisposition of mice transplanted with gene-modified hematopoietic precursors expressing flt3 ligand.
Blood.
1998;92:2003-2011 73. Gambacorti-Passerini C, Barni R, Marchesi E, et al. Sensitivity to the abl inhibitor STI571 in fresh leukaemic cells obtained from chronic myelogenous leukaemia patients in different stages of disease. Br J Haematol. 2001;112:972-974[CrossRef][Medline] [Order article via Infotrieve].
74.
Druker BJ, Talpaz M, Resta DJ, et al.
Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.
N Engl J Med.
2001;344:1031-1037 75. Zhao M, Kiyoi H, Yamamoto Y, et al. In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor. Leukemia. 2000;14:374-378[CrossRef][Medline] [Order article via Infotrieve].
© 2002 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  H. Haeno, R. L. Levine, D. G. Gilliland, and F. Michor A progenitor cell origin of myeloid malignancies PNAS, September 29, 2009; 106(39): 16616 - 16621. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fukuda, P. Singh, A. Moh, M. Abe, E. M. Conway, H. S. Boswell, S. Yamaguchi, X.-Y. Fu, and L. M. Pelus Survivin mediates aberrant hematopoietic progenitor cell proliferation and acute leukemia in mice induced by internal tandem duplication of Flt3 Blood, July 9, 2009; 114(2): 394 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Breitenbuecher, S. Schnittger, R. Grundler, B. Markova, B. Carius, A. Brecht, J. Duyster, T. Haferlach, C. Huber, and T. Fischer Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor Blood, April 23, 2009; 113(17): 4074 - 4077. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Schmidt-Arras, S.-A. Bohmer, S. Koch, J. P. Muller, L. Blei, H. Cornils, R. Bauer, S. Korasikha, C. Thiede, and F.-D. Bohmer Anchoring of FLT3 in the endoplasmic reticulum alters signaling quality Blood, April 9, 2009; 113(15): 3568 - 3576. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. von Bubnoff, R. A. Engh, E. Aberg, J. Sanger, C. Peschel, and J. Duyster FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro Cancer Res., April 1, 2009; 69(7): 3032 - 3041. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. G. Cornejo, M. G. Kharas, M. B. Werneck, S. L. Bras, S. A. Moore, B. Ball, M. Beylot-Barry, S. J. Rodig, J. C. Aster, B. H. Lee, et al. Constitutive JAK3 activation induces lymphoproliferative syndromes in murine bone marrow transplantation models Blood, March 19, 2009; 113(12): 2746 - 2754. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Nordigarden, M. Kraft, P. Eliasson, V. Labi, E. W.-F. Lam, A. Villunger, and J.-I. Jonsson BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3 Blood, March 5, 2009; 113(10): 2302 - 2311. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Akagi, L.-Y. Shih, M. Kato, N. Kawamata, G. Yamamoto, M. Sanada, R. Okamoto, C. W. Miller, D.-C. Liang, S. Ogawa, et al. Hidden abnormalities and novel classification of t(15;17) acute promyelocytic leukemia (APL) based on genomic alterations Blood, February 19, 2009; 113(8): 1741 - 1748. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weisberg, J. Roesel, G. Bold, P. Furet, J. Jiang, J. Cools, R. D. Wright, E. Nelson, R. Barrett, A. Ray, et al. Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells Blood, December 15, 2008; 112(13): 5161 - 5170. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. F. Tam, T.-L. Gu, J. Chen, B. H. Lee, L. Bullinger, S. Frohling, A. Wang, S. Monti, T. R. Golub, and D. G. Gilliland Id1 is a common downstream target of oncogenic tyrosine kinases in leukemic cells Blood, September 1, 2008; 112(5): 1981 - 1992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kikushige, G. Yoshimoto, T. Miyamoto, T. Iino, Y. Mori, H. Iwasaki, H. Niiro, K. Takenaka, K. Nagafuji, M. Harada, et al. Human Flt3 Is Expressed at the Hematopoietic Stem Cell and the Granulocyte/Macrophage Progenitor Stages to Maintain Cell Survival J. Immunol., June 1, 2008; 180(11): 7358 - 7367. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Loriaux, R. L. Levine, J. W. Tyner, S. Frohling, C. Scholl, E. P. Stoffregen, G. Wernig, H. Erickson, C. A. Eide, R. Berger, et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia Blood, May 1, 2008; 111(9): 4788 - 4796. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Weisberg, L. Banerji, R. D. Wright, R. Barrett, A. Ray, D. Moreno, L. Catley, J. Jiang, E. Hall-Meyers, M. Sauveur-Michel, et al. Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells Blood, April 1, 2008; 111(7): 3723 - 3734. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Li, O. Piloto, H. B. Nguyen, K. Greenberg, K. Takamiya, F. Racke, D. Huso, and D. Small Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse model Blood, April 1, 2008; 111(7): 3849 - 3858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Garzon, M. Garofalo, M. P. Martelli, R. Briesewitz, L. Wang, C. Fernandez-Cymering, S. Volinia, C.-G. Liu, S. Schnittger, T. Haferlach, et al. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin PNAS, March 11, 2008; 105(10): 3945 - 3950. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-G. Kim, K. Kojima, C. S. Swindle, C. V. Cotta, Y. Huo, V. Reddy, and C. A. Klug FLT3-ITD cooperates with inv(16) to promote progression to acute myeloid leukemia Blood, February 1, 2008; 111(3): 1567 - 1574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. V. Barry, J. J. Clark, J. Cools, J. Roesel, and D. G. Gilliland Uniform sensitivity of FLT3 activation loop mutants to the tyrosine kinase inhibitor midostaurin Blood, December 15, 2007; 110(13): 4476 - 4479. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Weisberg, A. L. Kung, R. D. Wright, D. Moreno, L. Catley, A. Ray, L. Zawel, M. Tran, J. Cools, G. Gilliland, et al. Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells Mol. Cancer Ther., July 1, 2007; 6(7): 1951 - 1961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice Blood, July 1, 2007; 110(1): 345 - 353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Mrozek, G. Marcucci, P. Paschka, S. P. Whitman, and C. D. Bloomfield Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification? Blood, January 15, 2007; 109(2): 431 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Knapper, A. K. Burnett, T. Littlewood, W. J. Kell, S. Agrawal, R. Chopra, R. Clark, M. J. Levis, and D. Small A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy Blood, November 15, 2006; 108(10): 3262 - 3270. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Knapper, K. I. Mills, A. F. Gilkes, S. J. Austin, V. Walsh, and A. K. Burnett The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases Blood, November 15, 2006; 108(10): 3494 - 3503. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Levis FLT3: the root of the problem Blood, October 15, 2006; 108(8): 2501 - 2502. [Full Text] [PDF]
|
|
|
|
|
|
J. L. Rocnik, R. Okabe, J.-C. Yu, B. H. Lee, N. Giese, D. P. Schenkein, and D. G. Gilliland Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITD Blood, August 15, 2006; 108(4): 1339 - 1345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Palmqvist, B. Argiropoulos, N. Pineault, C. Abramovich, L. M. Sly, G. Krystal, A. Wan, and R. K. Humphries The Flt3 receptor tyrosine kinase collaborates with NUP98-HOX fusions in acute myeloid leukemia Blood, August 1, 2006; 108(3): 1030 - 1036. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Wernig, T. Mercher, R. Okabe, R. L. Levine, B. H. Lee, and D. G. Gilliland Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model Blood, June 1, 2006; 107(11): 4274 - 4281. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Reindl, K. Bagrintseva, S. Vempati, S. Schnittger, J. W. Ellwart, K. Wenig, K.-P. Hopfner, W. Hiddemann, and K. Spiekermann Point mutations in the juxtamembrane domain of FLT3 define a new class of activating mutations in AML Blood, May 1, 2006; 107(9): 3700 - 3707. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Adam, V. Pogacic, M. Bendit, R. Chappuis, M. C. Nawijn, J. Duyster, C. J. Fox, C. B. Thompson, J. Cools, and J. Schwaller Targeting PIM Kinases Impairs Survival of Hematopoietic Cells Transformed by Kinase Inhibitor-Sensitive and Kinase Inhibitor-Resistant Forms of Fms-Like Tyrosine Kinase 3 and BCR/ABL. Cancer Res., April 1, 2006; 66(7): 3828 - 3835. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Amino, Y. Ideyama, M. Yamano, S. Kuromitsu, K. Tajinda, K. Samizu, H. Hisamichi, A. Matsuhisa, K. Shirasuna, M. Kudoh, et al. YM-359445, an Orally Bioavailable Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor, Has Highly Potent Antitumor Activity against Established Tumors Clin. Cancer Res., March 1, 2006; 12(5): 1630 - 1638. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. S. Radomska, D. S. Basseres, R. Zheng, P. Zhang, T. Dayaram, Y. Yamamoto, D. W. Sternberg, N. Lokker, N. A. Giese, S. K. Bohlander, et al. Block of C/EBP{alpha} function by phosphorylation in acute myeloid leukemia with FLT3 activating mutations J. Exp. Med., February 21, 2006; 203(2): 371 - 381. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Small FLT3 Mutations: Biology and Treatment Hematology, January 1, 2006; 2006(1): 178 - 184. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. H. Stover, J. Chen, B. H. Lee, J. Cools, E. McDowell, J. Adelsperger, D. Cullen, A. Coburn, S. A. Moore, R. Okabe, et al. The small molecule tyrosine kinase inhibitor AMN107 inhibits TEL-PDGFR{beta} and FIP1L1-PDGFR{alpha} in vitro and in vivo Blood, November 1, 2005; 106(9): 3206 - 3213. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Suzuki, H. Kiyoi, K. Ozeki, A. Tomita, S. Yamaji, R. Suzuki, Y. Kodera, S. Miyawaki, N. Asou, K. Kuriyama, et al. Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia Blood, October 15, 2005; 106(8): 2854 - 2861. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Frohling, C. Scholl, D. G. Gilliland, and R. L. Levine Genetics of Myeloid Malignancies: Pathogenetic and Clinical Implications J. Clin. Oncol., September 10, 2005; 23(26): 6285 - 6295. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Yang, L. Liu, D. Sternberg, L. Tang, I. Galinsky, D. DeAngelo, and R. Stone The FLT3 Internal Tandem Duplication Mutation Prevents Apoptosis in Interleukin-3-Deprived BaF3 Cells Due to Protein Kinase A and Ribosomal S6 Kinase 1-Mediated BAD Phosphorylation at Serine 112 Cancer Res., August 15, 2005; 65(16): 7338 - 7347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Choudhary, J. Schwable, C. Brandts, L. Tickenbrock, B. Sargin, T. Kindler, T. Fischer, W. E. Berdel, C. Muller-Tidow, and H. Serve AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations Blood, July 1, 2005; 106(1): 265 - 273. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Grundler, C. Miething, C. Thiede, C. Peschel, and J. Duyster FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model Blood, June 15, 2005; 105(12): 4792 - 4799. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bagrintseva, S. Geisenhof, R. Kern, S. Eichenlaub, C. Reindl, J. W. Ellwart, W. Hiddemann, and K. Spiekermann FLT3-ITD-TKD dual mutants associated with AML confer resistance to FLT3 PTK inhibitors and cytotoxic agents by overexpression of Bcl-x(L) Blood, May 1, 2005; 105(9): 3679 - 3685. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Di Croce Chromatin modifying activity of leukaemia associated fusion proteins Hum. Mol. Genet., April 15, 2005; 14(suppl_1): R77 - R84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Fukuda, H. E. Broxmeyer, and L. M. Pelus Flt3 ligand and the Flt3 receptor regulate hematopoietic cell migration by modulating the SDF-1{alpha}(CXCL12)/CXCR4 axis Blood, April 15, 2005; 105(8): 3117 - 3126. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. F. Landrette, Y.-H. Kuo, K. Hensen, S. B. van Waalwijk van Doorn-Khosrovani, P. N. Perrat, W. J. M. Van de Ven, R. Delwel, and L. H. Castilla Plag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11 Blood, April 1, 2005; 105(7): 2900 - 2907. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schwable, C. Choudhary, C. Thiede, L. Tickenbrock, B. Sargin, C. Steur, M. Rehage, A. Rudat, C. Brandts, W. E. Berdel, et al. RGS2 is an important target gene of Flt3-ITD mutations in AML and functions in myeloid differentiation and leukemic transformation Blood, March 1, 2005; 105(5): 2107 - 2114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Chen, M. Levis, P. Brown, K.-T. Kim, J. Allebach, and D. Small FLT3/ITD Mutation Signaling Includes Suppression of SHP-1 J. Biol. Chem., February 18, 2005; 280(7): 5361 - 5369. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. George, P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, et al. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3 Blood, February 15, 2005; 105(4): 1768 - 1776. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Fiedler, H. Serve, H. Dohner, M. Schwittay, O. G. Ottmann, A.-M. O'Farrell, C. L. Bello, R. Allred, W. C. Manning, J. M. Cherrington, et al. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease Blood, February 1, 2005; 105(3): 986 - 993. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Brown, M. Levis, S. Shurtleff, D. Campana, J. Downing, and D. Small FLT3 inhibition selectively kills childhood acute lymphoblastic leukemia cells with high levels of FLT3 expression Blood, January 15, 2005; 105(2): 812 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Wadleigh, D. J. DeAngelo, J. D. Griffin, and R. M. Stone After chronic myelogenous leukemia: tyrosine kinase inhibitors in other hematologic malignancies Blood, January 1, 2005; 105(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. M. Stone, D. J. DeAngelo, V. Klimek, I. Galinsky, E. Estey, S. D. Nimer, W. Grandin, D. Lebwohl, Y. Wang, P. Cohen, et al. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412 Blood, January 1, 2005; 105(1): 54 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Y. Chung, G. Morrone, J. J. Schuringa, B. Wong, D. C. Dorn, and M. A. S. Moore Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis Blood, January 1, 2005; 105(1): 77 - 84. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Koschmieder, B. Gottgens, P. Zhang, J. Iwasaki-Arai, K. Akashi, J. L. Kutok, T. Dayaram, K. Geary, A. R. Green, D. G. Tenen, et al. Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis Blood, January 1, 2005; 105(1): 324 - 334. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kindler, F. Breitenbuecher, S. Kasper, E. Estey, F. Giles, E. Feldman, G. Ehninger, G. Schiller, V. Klimek, S. D. Nimer, et al. Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML) Blood, January 1, 2005; 105(1): 335 - 340. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. H. Yee, M. Schittenhelm, A.-M. O'Farrell, A. R. Town, L. McGreevey, T. Bainbridge, J. M. Cherrington, and M. C. Heinrich Synergistic effect of SU11248 with cytarabine or daunorubicin on FLT3 ITD-positive leukemic cells Blood, December 15, 2004; 104(13): 4202 - 4209. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Lacayo, S. Meshinchi, P. Kinnunen, R. Yu, Y. Wang, C. M. Stuber, L. Douglas, R. Wahab, D. L. Becton, H. Weinstein, et al. Gene expression profiles at diagnosis in de novo childhood AML patients identify FLT3 mutations with good clinical outcomes Blood, November 1, 2004; 104(9): 2646 - 2654. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Clark, J. Cools, D. P. Curley, J.-C. Yu, N. A. Lokker, N. A. Giese, and D. G. Gilliland Variable sensitivity of FLT3 activation loop mutations to the small molecule tyrosine kinase inhibitor MLN518 Blood, November 1, 2004; 104(9): 2867 - 2872. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. J. Griswold, L. J. Shen, P. La Rosee, S. Demehri, M. C. Heinrich, R. M. Braziel, L. McGreevey, A. D. Haley, N. Giese, B. J. Druker, et al. Effects of MLN518, a dual FLT3 and KIT inhibitor, on normal and malignant hematopoiesis Blood, November 1, 2004; 104(9): 2912 - 2918. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Jiang, J. G. Paez, J. C. Lee, R. Bo, R. M. Stone, D. J. DeAngelo, I. Galinsky, B. M. Wolpin, A. Jonasova, P. Herman, et al. Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML Blood, September 15, 2004; 104(6): 1855 - 1858. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, H. Li, M.-N. Wang, D. Lu, R. Bassi, Y. Wu, H. Zhang, P. Balderes, D. L. Ludwig, B. Pytowski, et al. Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody Blood, August 15, 2004; 104(4): 1137 - 1144. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Bali, P. George, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, A. Scuto, S. Annavarapu, W. Fiskus, et al. Superior Activity of the Combination of Histone Deacetylase Inhibitor LAQ824 and the FLT-3 Kinase Inhibitor PKC412 against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 Clin. Cancer Res., August 1, 2004; 10(15): 4991 - 4997. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Loh and K. M. Shannon A "Ras-in-ALL" model of signaling? Blood, July 15, 2004; 104(2): 297 - 298. [Full Text] [PDF]
|
|
|
|
|
|
L. C. Platanias SMRT interactions, repression, and Flt3-ITD Blood, June 15, 2004; 103(12): 4382 - 4382. [Full Text] [PDF]
|
|
|
|
|
|
S. Takahashi, M. J. McConnell, H. Harigae, M. Kaku, T. Sasaki, A. M. Melnick, and J. D. Licht The Flt3 internal tandem duplication mutant inhibits the function of transcriptional repressors by blocking interactions with SMRT Blood, June 15, 2004; 103(12): 4650 - 4658. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. T. Le, N. Kong, Y. Zhu, J. O. Lauchle, A. Aiyigari, B. S. Braun, E. Wang, S. C. Kogan, M. M. Le Beau, L. Parada, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder Blood, June 1, 2004; 103(11): 4243 - 4250. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. George, P. Bali, P. Cohen, J. Tao, F. Guo, C. Sigua, A. Vishvanath, W. Fiskus, A. Scuto, S. Annavarapu, et al. Cotreatment with 17-Allylamino-Demethoxygeldanamycin and FLT-3 Kinase Inhibitor PKC412 Is Highly Effective against Human Acute Myelogenous Leukemia Cells with Mutant FLT-3 Cancer Res., May 15, 2004; 64(10): 3645 - 3652. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. D. Smith, M. Levis, M. Beran, F. Giles, H. Kantarjian, K. Berg, K. M. Murphy, T. Dauses, J. Allebach, and D. Small Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia Blood, May 15, 2004; 103(10): 3669 - 3676. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Bagrintseva, R. Schwab, T. M. Kohl, S. Schnittger, S. Eichenlaub, J. W. Ellwart, W. Hiddemann, and K. Spiekermann Mutations in the tyrosine kinase domain of FLT3 define a new molecular mechanism of acquired drug resistance to PTK inhibitors in FLT3-ITD-transformed hematopoietic cells Blood, March 15, 2004; 103(6): 2266 - 2275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Zheng, A. D. Friedman, M. Levis, L. Li, E. G. Weir, and D. Small Internal tandem duplication mutation of FLT3 blocks myeloid differentiation through suppression of C/EBP{alpha} expression Blood, March 1, 2004; 103(5): 1883 - 1890. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Taketani, T. Taki, K. Sugita, Y. Furuichi, E. Ishii, R. Hanada, M. Tsuchida, K. Sugita, K. Ida, and Y. Hayashi FLT3 mutations in the activation loop of tyrosine kinase domain are frequently found in infant ALL with MLL rearrangements and pediatric ALL with hyperdiploidy Blood, February 1, 2004; 103(3): 1085 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Braun, D. A. Tuveson, N. Kong, D. T. Le, S. C. Kogan, J. Rozmus, M. M. Le Beau, T. E. Jacks, and K. M. Shannon Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder PNAS, January 13, 2004; 101(2): 597 - 602. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Gilliland, C. T. Jordan, and C. A. Felix The Molecular Basis of Leukemia Hematology, January 1, 2004; 2004(1): 80 - 97. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. O'Farrell, J. M. Foran, W. Fiedler, H. Serve, R. L. Paquette, M. A. Cooper, H. A. Yuen, S. G. Louie, H. Kim, S. Nicholas, et al. An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients Clin. Cancer Res., November 15, 2003; 9(15): 5465 - 5476. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M. Zwaan, S. Meshinchi, J. P. Radich, A. J. P. Veerman, D. R. Huismans, L. Munske, M. Podleschny, K. Hahlen, R. Pieters, M. Zimmermann, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance Blood, October 1, 2003; 102(7): 2387 - 2394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Wong, J. McLaughlin, D. Cheng, K. Shannon, L. Robb, and O. N. Witte IL-3 receptor signaling is dispensable for BCR-ABL-induced myeloproliferative disease PNAS, September 30, 2003; 100(20): 11630 - 11635. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Murata, H. Kumagai, T. Kawashima, K. Tamitsu, M. Irie, H. Nakajima, S. Suzu, M. Shibuya, S. Kamihira, T. Nosaka, et al. Selective Cytotoxic Mechanism of GTP-14564, a Novel Tyrosine Kinase Inhibitor in Leukemia Cells Expressing a Constitutively Active Fms-like Tyrosine Kinase 3 (FLT3) J. Biol. Chem., August 29, 2003; 278(35): 32892 - 32898. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. M. Le Beau, E. M. Davis, B. Patel, V. T. Phan, J. Sohal, and S. C. Kogan Recurring chromosomal abnormalities in leukemia in PML-RARA transgenic mice identify cooperating events and genetic pathways to acute promyelocytic leukemia Blood, August 1, 2003; 102(3): 1072 - 1074. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Karsunky, M. Merad, A. Cozzio, I. L. Weissman, and M. G. Manz Flt3 Ligand Regulates Dendritic Cell Development from Flt3+ Lymphoid and Myeloid-committed Progenitors to Flt3+ Dendritic Cells In Vivo J. Exp. Med., July 21, 2003; 198(2): 305 - 313. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Grundler, C. Thiede, C. Miething, C. Steudel, C. Peschel, and J. Duyster Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor Blood, July 15, 2003; 102(2): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Spiekermann, K. Bagrintseva, R. Schwab, K. Schmieja, and W. Hiddemann Overexpression and Constitutive Activation of FLT3 Induces STAT5 Activation in Primary Acute Myeloid Leukemia Blast Cells Clin. Cancer Res., June 1, 2003; 9(6): 2140 - 2150. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-M. O'Farrell, T. J. Abrams, H. A. Yuen, T. J. Ngai, S. G. Louie, K. W. H. Yee, L. M. Wong, W. Hong, L. B. Lee, A. Town, et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo Blood, May 1, 2003; 101(9): 3597 - 3605. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Mizuki, J. Schwable, C. Steur, C. Choudhary, S. Agrawal, B. Sargin, B. Steffen, I. Matsumura, Y. Kanakura, F. D. Bohmer, et al. Suppression of myeloid transcription factors and induction of STAT response genes by AML-specific Flt3 mutations Blood, April 15, 2003; 101(8): 3164 - 3173. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Sohal, V. T. Phan, P. V. Chan, E. M. Davis, B. Patel, L. M. Kelly, T. J. Abrams, A. M. O'Farrell, D. G. Gilliland, M. M. Le Beau, et al. A model of APL with FLT3 mutation is responsive to retinoic acid and a receptor tyrosine kinase inhibitor, SU11657 Blood, April 15, 2003; 101(8): 3188 - 3197. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Spiekermann, R. J. Dirschinger, R. Schwab, K. Bagrintseva, F. Faber, C. Buske, S. Schnittger, L. M. Kelly, D. G. Gilliland, and W. Hiddemann The protein tyrosine kinase inhibitor SU5614 inhibits FLT3 and induces growth arrest and apoptosis in AML-derived cell lines expressing a constitutively activated FLT3 Blood, February 15, 2003; 101(4): 1494 - 1504. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Ravandi, M. Talpaz, and Z. Estrov Modulation of Cellular Signaling Pathways: Prospects for Targeted Therapy in Hematological Malignancies Clin. Cancer Res., February 1, 2003; 9(2): 535 - 550. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Lowenberg, J. D. Griffin, and M. S. Tallman Acute Myeloid Leukemia and Acute Promyelocytic Leukemia Hematology, January 1, 2003; 2003(1): 82 - 101. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Qian, A. A. Fernald, L. A. Godley, R. A. Larson, and M. M. Le Beau Expression profiling of CD34+ hematopoietic stem/ progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia PNAS, November 12, 2002; 99(23): 14925 - 14930. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Spiekermann, K. Bagrintseva, C. Schoch, T. Haferlach, W. Hiddemann, and S. Schnittger A new and recurrent activating length mutation in exon 20 of the FLT3 gene in acute myeloid leukemia Blood, October 16, 2002; 100(9): 3423 - 3425. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. H. Yee, A. M. O'Farrell, B. D. Smolich, J. M. Cherrington, G. McMahon, C. L. Wait, L. S. McGreevey, D. J. Griffith, and M. C. Heinrich SU5416 and SU5614 inhibit kinase activity of wild-type and mutant FLT3 receptor tyrosine kinase Blood, September 26, 2002; 100(8): 2941 - 2949. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Gilliland and J. D. Griffin The roles of FLT3 in hematopoiesis and leukemia Blood, August 13, 2002; 100(5): 1532 - 1542. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. M. Abu-Duhier, A. C. Goodeve, G. A. Wilson, R. S. Carr, I. R. Peake, and J. T. Reilly FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia Blood, June 17, 2002; 100(1): 364 - 364. [Full Text] [PDF]
|
|
|
|
|
|
D. G. B. Leonard, L. B. Travis, K. Addya, G. M. Dores, E. J. Holowaty, K. Bergfeldt, D. Malkin, B. A. Kohler, C. F. Lynch, T. Wiklund, et al. p53 Mutations in Leukemia and Myelodysplastic Syndrome after Ovarian Cancer Clin. Cancer Res., May 1, 2002; 8(5): 973 - 985. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2002 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
)
R, TEL/JAK2, HIP1/PDGF
80°C. Viral titers were estimated by transduction of Ba/F3 cells in
the presence of Polybrene (10 µg/mL) as described
previously.
fusion proteins,
respectively
, RAS-GTPase activating protein, the p85 subunit of
PI3K, SHC, GRB2, STAT5, VAV, FYN, and SRC, among
others.